<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01907724</url>
  </required_header>
  <id_info>
    <org_study_id>1894-007</org_study_id>
    <secondary_id>IDX-06A-007</secondary_id>
    <nct_id>NCT01907724</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)</brief_title>
  <official_title>A Phase I, Randomized, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential for a PK drug-drug interaction when
      IDX719, simeprevir, TMC647055 and low-dose ritonavir (RTV) are administered in combination.
      Safety and tolerability will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed maximum plasma drug concentration (Cmax)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum concentration (Tmax)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the drug concentration-plasma time curve from time zero to last measurable concentration (AUC0-t)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Predose trough concentration (Ctrough)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination rate constant</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed terminal half-life (T1/2)</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing serious adverse events (SAEs)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing adverse events (AEs)</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Grade 1-4 laboratory abnormalities</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>IDX719 + RTV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants take IDX719 150 mg once daily (QD) + ritonavir 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simeprevir/TMC647055 + RTV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants take simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDX719</intervention_name>
    <description>IDX719 will be supplied as a 50 mg tablet for oral administration.</description>
    <arm_group_label>IDX719 + RTV</arm_group_label>
    <arm_group_label>Simeprevir/TMC647055 + RTV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <description>Simeprevir will be supplied as 75 mg capsules for oral administration.</description>
    <arm_group_label>IDX719 + RTV</arm_group_label>
    <arm_group_label>Simeprevir/TMC647055 + RTV</arm_group_label>
    <other_name>Olysio™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMC647055</intervention_name>
    <description>TMC647055 will be supplied as 150 mg capsules for oral administration.</description>
    <arm_group_label>IDX719 + RTV</arm_group_label>
    <arm_group_label>Simeprevir/TMC647055 + RTV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTV</intervention_name>
    <description>RTV will be supplied as 80 mg/mL solution for oral administration.</description>
    <arm_group_label>IDX719 + RTV</arm_group_label>
    <arm_group_label>Simeprevir/TMC647055 + RTV</arm_group_label>
    <other_name>Norvir™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agrees to use a double method of birth control (one of which must be a barrier) from
             Screening through at least 90 days after the last dose of the study drug

          -  Male participants agree not to donate sperm from Day -1 through 90 days after the last
             dose of study drug

        Exclusion Criteria:

          -  Is pregnant or breastfeeding

          -  Has another clinically significant medical conditions or laboratory abnormality(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>July 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Hepatitis C virus</keyword>
  <keyword>HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

